Literature DB >> 29137289

Lingguizhugan decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: a whole trancriptome study by RNA-Seq.

Mingzhe Zhu1,2, Shijun Hao1, Tao Liu1, Lili Yang1, Peiyong Zheng1, Li Zhang1, Guang Ji1.   

Abstract

Lingguizhugan decoction, a classic traditional Chinese medicine formula, has been used to treat non-alcoholic fatty liver disease (NAFLD), however, the underlying mechanisms remains unclear. In the present study, we compared the phenotype of the normal rats (fed with chow diet), high-fat-diet (HFD) induced NAFLD rats and Lingguizhugan decoction (LGZG, comprises four Chinese herbs: Poria, Ramulus Cinnamomi, Rhizoma Atractylodis Macrocephalae, and Radix Glycyrrhizae.) intervened rats, and detected whole genome gene expression by RNA-Seq. Our results demonstrated that LGZG decoction attenuated phenotypic characteristics of NAFLD rats. RNA-Seq data analysis revealed that gene expression profiles exerted differential patterns between different groups. 2690 (1445 up-regulated, 1245 down-regulated) genes in NAFLD versus (vs) normal group, 69 (16 up-regulated, 53 down-regulated) genes in LGZG vs NAFLD group, and 42 overlapped (12 up- regulated, 30 down-regulated) genes between NAFLDvs normal group and LGZG vs NAFLD group were identified as differentially expressed. GO, pathway enrichment and PPI networks analysis of the overlapped genes revealed that LGZG decoction might attenuate NAFLD possibly by affecting insulin resistance and lipid metabolism related pathways (e.g., PI3K-Akt, AMPK). Differentially expressed genes involved in these pathways such as Pik3r1, Foxo1, Foxo3, Scd1, Col3a1 and Fn1 might be candidate targets for treating NAFLD.

Entities:  

Keywords:  Lingguizhugan decoction; RNA-Seq; gene expression; non-alcoholic fatty liver disease

Year:  2017        PMID: 29137289      PMCID: PMC5669915          DOI: 10.18632/oncotarget.19734

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver diseases around the world, which is characterized by accumulation of fat deposits in the liver resulting from causes other than alcohol abuse [1, 2]. Prevalence of NAFLD has been increasing due to the modern sedentary and food-abundant lifestyle, which is 20-30% in western countries and 15-20% in China [3, 4]. Importantly, NAFLD is one of the most dangerous complications that can lead to severe liver pathologies, including fibrosis, cirrhosis and hepatocellular carcinoma [5, 6]. In addition, accumulating evidence indicates that the risks of NAFLD extend beyond the liver and are associated with a range of chronic diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes mellitus [7, 8]. Development of NAFLD is related to several factors such as age, gender, ethnicity, presence of sleep apnea and endocrine system disorders (e.g., hypothyroidism, hypopituitarism, hypogonadism, and polycystic ovarian syndrome). Prevalence of NAFLD increases with age and is more common among males aged 45-65 years. It is also spreading rapidly among children along with obesity epidemics [9]. Thus, NAFLD has become a major global health problem and brought heavy burden to patients and society. The mechanisms involved in the development of NAFLD are still under debate, although several hypotheses have been proposed [10-12]. Studies have revealed that various signaling pathways such as nuclear factor κB (NF-κB), AMP-activated protein kinase (AMPK), Toll-like receptor (TLR) and phosphatidylinositol 3- kinase/protein kinase B (PI3K/Akt) are involved in the progress of NAFLD. These signaling pathways are interconnected to form a network, blocking any one of them may not be effective to prevent or treat the NAFLD [13]. Actually, there is no established standard therapy for NAFLD. International guidelines recommend that lifestyle changes as the main strategies suggested for NAFLD patients. However, pharmacological intervention are needed when the disease are progressive or serious. Recently, many complementary therapies, especially herbal medicines have been introduced to treat NAFLD [14]. Traditional Chinese medicine has been used for the treatment of suboptimal health from the perspective of predictive, preventive and personalized medicine (PPPM), which may be a cost-effective way for preventing chronic diseases [15]. Of note, a number of traditional Chinese medicines have been evaluated in treating NAFLD in the past decades. Lingguizhugan decoction is an ancient Chinese herbal formula from a classic book of traditional Chinese medicine titled Jingui Yaolue. Recently, Lingguizhugan decoction has been applied to prevent metabolic syndrome and may exhibit effects in alleviating obesity, hyperglycemia, hyperlipidemia, hypertension and hepatic injury [16]. It is reported that the modified Lingguizhugan decoction combined with short-term very low calorie diets could be safely implemented for steady glycemic control in newly diagnosed type 2 diabetes mellitus patients [17].Other researchers revealed that Lingguizhugan decoction combined calorie restriction could reduce the body weight, fasting plasma glucose and insulin resistance index in high fat diet feeding rat [18]. Our previous study also showed that Lingguizhugan decoction could attenuate HFD induced NAFLD, as measured by body weight, liver injury and hepatic triglyceride (TG) [19]. However, the underlying mechanisms of Lingguizhugan decoction on NAFLD remain unclear. To enhance our understanding of the mechanisms under the efficacy of Lingguizhugan decoction, we applied HFD induced NAFLD rats and firstly detected hepatic whole genome gene expression profile by RNA-Seq analysis. The present study may shed new lights on understanding the scientific connotation of traditional Chinese medicine therapeutic principle in NAFLD and provide more options for treating NAFLD and candidate targets for clinical therapy of NAFLD in the future.

RESULTS

Phenotypic characteristics of the rats

HFD feeding induced steatosis, which is the typical characteristic of NAFLD in liver sections as demonstrated by hematoxylin and eosin (H&E) staining and Oil Red O staining (Figure 1I), significantly increased hepatic TG (Figure 1H) in NAFLD rats was consistent with the histological alteration. The bodyweight (Figure 1A), liver index (Figure 1B), Epididymal Fat Pad-Body Weight Ratio (EFP/BW, Figure 1C), serum total cholesterol (TC, Figure 1D), serum aspartate aminotransferase (AST, Figure 1G) were also dramatically increased in NAFLD rats, but serum TG (Figure 1E) and almandine aminotransferase (ALT, Figure 1F) showed no significantly difference between groups. After 4-week Lingguizhugan decoction treatment, steatosis was attenuated (Figure 1I) and hepatic TG content were significantly decreased (Figure 1H). Liver index, EFP/BW ratio (Figure 1C), serum TC (Figure 1D), TG (Figure 1E) and AST (Figure 1G) were also markedly decreased upon Lingguizhugan decoction intervention, whereas body weight (Figure 1A) and serum ALT (Figure 1F) did not respond to the intervention.
Figure 1

The phenotypic characteristics of the rats Male C57Bl/6 mice were either fed chow diet (Normal, n=7), HFD (n=7) or HFD with Lingguizhugan decoction administrated (n=7) for 4 weeks

The rats were sacrificed, and liver tissue and serum were collected. Body weight was recorded (A), liver index (B), Epididymal Fat Pad-Body Weight Ratio (C) were calculated. Serum TC (D), TG (E), ALT (F), AST (G) were analyzed, liver TG content (H) was detected, and liver sections were stained with both H&E and oil Red O (I) ( image magnification ×200). Data were present as mean ± SD.Green bars, lingguizhugan decoction intervened group; blue bars, HFD induced NAFLD group; black bars, normal group. Two compared groups were marked with a line and statistical information was given as p<0.05 or p>0.05.

The phenotypic characteristics of the rats Male C57Bl/6 mice were either fed chow diet (Normal, n=7), HFD (n=7) or HFD with Lingguizhugan decoction administrated (n=7) for 4 weeks

The rats were sacrificed, and liver tissue and serum were collected. Body weight was recorded (A), liver index (B), Epididymal Fat Pad-Body Weight Ratio (C) were calculated. Serum TC (D), TG (E), ALT (F), AST (G) were analyzed, liver TG content (H) was detected, and liver sections were stained with both H&E and oil Red O (I) ( image magnification ×200). Data were present as mean ± SD.Green bars, lingguizhugan decoction intervened group; blue bars, HFD induced NAFLD group; black bars, normal group. Two compared groups were marked with a line and statistical information was given as p<0.05 or p>0.05.

Differentially expressed gene profiles

Using the cutoff false discovery rate<0.05 and fold change>1.2 (up- regulated) or<0.83(down-regulated), we identified 2690 (1445 up- regulated, 1245 down-regulated) differentially expressed genes in NAFLD group comparing to normal group. Interestingly, we observed Lingguizhugan decoction altered gene expression profiles and identified 69 (16 up-regulated, 53 down-regulated) differentially expressed genes in Lingguizhugan decoction intervention group (LGZG) in comparison to NAFLD group. We also identified 42 overlapped (12 up- regulated, 30 down- regulated) genes between NAFLD vs normal group and LGZG vs NAFLD group. The differentially expressed genes in NAFLD vs normal and LGZG vs NAFLD were listed in supplementary file 1. The overlapped differentially expressed genesbetween NAFLD vs normal group and LGZG vs NAFLD group were listed in Table 1 .
Table 1

The overlapped differentially expressed genes list

Gene_symbolFold changeNAFLDVs normalFDRNAFLDVs normalFold changeLGZGvs NAFLDFDRLGZGvs NAFLD
Actn41.2200.0240.7970.029
Ahr1.3780.0190.6630.046
Alas11.2280.0170.6440.004
Apon0.7400.0041.3300.031
Avpr1a1.3410.0230.6220.040
Bcl2l111.7080.0170.5560.028
Col3a11.2950.0150.7340.006
Ech10.6450.0021.4120.026
Fads20.5230.0040.7270.041
Fn11.2950.0160.7640.016
Foxo11.6450.0220.4940.032
Foxo31.5620.0330.4260.012
Fzd11.2710.0300.5200.025
Gstt31.2810.0181.3560.047
Hfe20.6580.0071.6370.028
Hspa80.6960.0010.7910.027
Igfbp71.2820.0170.7230.040
Insig10.6980.0160.4000.003
Irf2bp21.4220.0220.5420.037
Lpin11.5180.0160.4060.000
Lrp11.2030.0200.8230.016
Mafb1.4780.0150.5330.025
Osgin10.4270.0042.3600.004
Pik3r11.2920.0270.5350.003
Ppp1r3c2.3850.0020.3610.000
Rapgef51.5020.0300.4900.047
Rasgef1b2.0730.0120.4290.010
Rnf1860.1390.0084.7260.033
Scd11.8660.0110.5610.023
Slc25a321.3230.0250.4400.000
Slc38a21.5400.0050.4830.000
Tmem21.6690.0150.6210.049
Tp53inp12.1220.0160.4020.019
Tsc22d31.4640.0160.5820.018
Zfp1892.3680.0070.3660.010
Furthermore, we performed hierarchical cluster analysis for the overlapped genes and observed distinctly different patterns of gene expression. As shown in Figure 2, most of the differentially expressed genes in NAFLD vs normal group had the opposite expression patterns in LGZG vs NAFLD group, e.g. Pik3r1, Forkhead O transcription factors 1 (Foxo1), stearoyl CoA desaturase 1 (Scd1) were up-regulated in NAFLD rats, whereas down-regulated in LGZG group. Additionally, genes enriched in PI3K/Akt and AMPK pathways also exhibited different expression patterns.
Figure 2

Hierarchical cluster for the overlap differentially expressed genes All the relevant genes were grouped by hierarchical clustering based on expression values (log2 ratios) across all the samples

Samples are displayed in columns and genes in rows. Gene expression is represented as a color, with brighter red for higher values and brighter green for lower values.

Hierarchical cluster for the overlap differentially expressed genes All the relevant genes were grouped by hierarchical clustering based on expression values (log2 ratios) across all the samples

Samples are displayed in columns and genes in rows. Gene expression is represented as a color, with brighter red for higher values and brighter green for lower values.

Gene annotation and functional analysis

To examine whether there was recognizable biological relevance to the gene expression patterns, further gene annotation and functional analysis were performed for the 42 overlapped differentially expressed genes. Using David 6.8, we noticed that 35 were known and 7 were unknown genes. Functional category of the overlapped genes was classified into Gene Ontology (GO) terms such as cellular response to insulin stimulus, response to drug, response to fatty acid and positive regulation of apoptotic process (Figure 3A). The detailed information for GO terms of overlapped genes was listed in supplementary file 2. Pathway enrichment analysis revealed that 21 overlapped genes were enriched in Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways such as AMPK signaling pathway, PI3K-Akt signaling pathway and Foxo signaling pathway (Figure 3B). For instance, Foxo1, Foxo3, Pik3r1 and Scd1 were enriched in AMPK signaling pathway, Bcl2l11, Col3a1, Fn1, Foxo1, Foxo3 and Pik3r1 were enriched in PI3K/Akt signaling pathway. Of note, Foxo1, Foxo3, Pik3r1, Scd1, Bcl2l11, Col3a1 and Fn1 were up-regulated in NAFLD group, which were significantly decreased by Lingguizhugan decoction. The detailed information for the pathway enrichment was listed in Table 2. Gene annotation, GO and KEGG pathway analysis all revealed that the main differentially expressed genes altered by Lingguizhugan decoction were mainly focused on insulin resistance and lipid metabolism related functions.
Figure 3

GO and KEGG pathway enrichment GO and KEGG pathway enrichment were analyzed by David 6.8

GO (biological process) terms enriched for overlapped differentially expressed genes (A) KEGG pathway enrichment for overlapped differentially expressed genes (B).

Table 2

The overlapped differentially expressed genes pathway enrichment

KEGG pathway nameGenes enriched in pathwayP Value
AmoebiasisFN1, Col3a1 Actn4, Pik3r10.002
AMPK signaling pathwayFoxo1, Foxo3, Scd1, Pik3r10.003
FoxO signaling pathwayFoxo1, Foxo3, Bcl2l11, Pik3r10.004
PI3K-Akt signaling pathwayBcl2l11, Col3a1, Fn1, Foxo1, Foxo3, and Pik3r10.008
Focal adhesionFn1, Col3a1, Actn4, Pik3r10.014
Insulin resistanceFoxo1, Ppp1r3c, Pik3r10.029
Insulin signaling pathwayFoxo1, Ppp1r3c, Pik3r10.045
Biosynthesis of unsaturated fatty acidsScd1, Fads20.069
Pathways in cancerFoxo1, Fn1, Fzd1, Pik3r10.070
Proteoglycans in cancerFn1, Fzd1, Pik3r10.085
Regulation of actin cytoskeletonFn1, Actn4, Pik3r10.098

GO and KEGG pathway enrichment GO and KEGG pathway enrichment were analyzed by David 6.8

GO (biological process) terms enriched for overlapped differentially expressed genes (A) KEGG pathway enrichment for overlapped differentially expressed genes (B).

Protein-protein interaction (PPI) network for the overlapped genes

PPI network of the overlapped differentially expressed genes was constructed by Cytoscape based on BioGRID database. Hub proteins indicated that the connectivity among the nodes was tightly established. As shown in Figure 4, we observed 23 differentially expressed genes encoding proteins were involved in the network such as Foxo1, Foxo3, PIK3R1, FN1, BCL2L11and COL3A1, of which, PIK3R1 was the most important hub protein.
Figure 4

PPI network for the overlapped differentially expressed genes

The yellow nodes represent overlapped differentially expressed genes encoding proteins, which are interacted with the predicted proteins (blue nodes).

PPI network for the overlapped differentially expressed genes

The yellow nodes represent overlapped differentially expressed genes encoding proteins, which are interacted with the predicted proteins (blue nodes).

DISCUSSION

In the present study, applying RNA-seq analysis, we observed that Lingguizhugan decoction could improve the phenotypic characteristics of NAFLD and alter a batch of gene expression. By literature retrieval, we found most of the identified differentially expressed genes were related to NAFLD. Furthermore, using the combination of gene annotation, GO, KEGG pathway and PPI network analysis, we noticed that most of the genes altered by Lingguizhugan decoction were insulin resistance and lipid metabolism related genes. Insulin resistance is pivotal for the progression of NAFLD [20]. Insulin signal transduction involves a cascade of factors, including insulin receptor desensitization, insulin receptor substrate (IRS), PI3K, and Foxo activated gene transcriptional profiling [21]. PI3K pathway plays an important role in the development of insulin resistance. PI3K belongs to the class 1a 3-kinases, which exist as heterodimers, consisting of a regulatory subunit (p85) and a catalytic subunit (p110). The abundance of p85 and p110 can alter PI3K activity. Accumulating evidence has shown that increased expression of PI3K p85 contributes to the pathogenesis of insulin resistance [22]. Xu D, et al [23] has reported PI3K p85 was significant higher in NAFLD patients compared with the control patients, which is in agreement with our present observation. Interestingly, PI3K p85 was significantly decreased by Lingguizhugan decoction, indicating that Lingguizhugan decoction might regulate the function of PI3K p85 to enhance PI3K activity, alleviate insulin resistance and improve NAFLD. FOXOs play a critical role in the integration of hormonal and nutritional signals for metabolic control. As a downstream mediator of insulin signaling, the activity of FOXOs is attenuated by PI3K/Akt [24]. FOXO1 is a direct transcriptional regulator of gluconeogenesis, and has profound effects on hepatic insulin resistance and lipid metabolism. FOXO3 is required for antioxidant responses and autophagy, its expression alters in liver diseases. A number of studies suggest that inactivation of FOXOs may block insulin resistance and decrease the risk of mortality from diabetes mellitus [25]. However, relatively less is known about FOXOs in NAFLD and controversial data were found. Valenti L, et al [26] reported that FOXO1 expression and activity are increased in patients with nonalcoholic steatohepatitis (NASH). In contrast, Pan X, et al [27] observed FOXOs play a salutary role in protecting mice against the diet induced fatty liver disease. In the present study, we observed Foxo1 and Foxo3 were up-regulated in NAFLD rats and remarkably reduced by Lingguizhugan decoction treatment. However, only through future investigations can safely and effectively develop FOXOs into viable clinical treatments for NAFLD. Lipid metabolism alteration is another important factor for the progression of NAFLD. AMPK, is a heterologous trimeric protein kinase (composing of a catalytic α subunit and regulatory β, γ subunits), which is a central regulator of cellular energy balance and metabolic control, plays an important role in hepatic lipid metabolism [28]. Activation of AMPK directly suppresses activity of sterol regulatory element- binding protein-1c and -2 (SREBP-1c, SREBP-2), leading to decreased SREBP-1c target gene expression, including acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FAS), and Scd1 transcription and translation, resulting in reduced lipid accumulation and improved liver condition [29]. We observed that Lingguizhugan decoction altered AMPK signaling pathway. For instance, gene Prkab1 encoding AMPKβ1was reduced in NAFLD rats and increased (1.5 fold) by Lingguizhugan decoction treatment, which deserved to be further investigation. Literature searching revealed that the main functional subunit of AMPK is AMPKα. Although rare data was reported for the correlation of AMPKβ1with NAFLD, it has been recorded that genetic deletion of the AMPK β1 subunit in mice displayed enhanced adipose tissue macrophage inflammation and hepatic insulin resistance [30]. Another study found that metformin and salicylate, which interacted directly at the AMPKβ1 drug-binding site, could reduce lipogenesis and enhance insulin sensitivity in mice [31]. Scd1 is a rate-limiting enzyme catalyzing the synthesis of monounsaturated fatty acids, which are major components of tissue lipids. Scd1 has been shown to be a crucial factor in lipid metabolism as a critical control point regulating hepatic lipid synthesis and β-oxidation [32].The genetic deletion of Scd1 protects against the development of fatty liver and insulin resistance in mice. Besides, antisense nucleotide inhibitors against hepatic Scd1 prevent HFD induced hepatic steatosis, and Scd1 inhibitors are claimed to be new treatments for NASH [33]. Our findings in the present study were consistent with these data, indicating Lingguizhugan decoction might decrease Scd1 and prevent the progress of NAFLD. Further investigation on the mechanisms of Scd1 regulation may help finding new drugs for NAFLD treatment. Moreover, we also noticed some other genes such as Col3a1 and Fn1 were significantly down-regulated by Lingguizhugan decoction. Col3a1 transcripts into collagen alpha-1(III) chain protein, which is a precursor to collagen III, while Fn1 encodes glycoprotein fibronectin, the ligand of extracellular matrix components. These two genes are actively involved into the fibrosis process. Of note, Zhang X, et al [34] has reported that dioscin exhibited potent effects against liver fibrosis through modulation of Col3a1 expression. Chen G, et al [35] found that gossypol ameliorated liver fibrosis and reduced Col3a1and Fn1 levels. Bai Q, et al [36] reported that acetaminophen hepatotoxic metabolite, increased cellular mRNA expression of Col3a1 and induced liver fibrosis. All these data suggested that Col3a1and Fn1 play an important role in the progression of NAFLD and Lingguizhugan decoction might down- regulate Col3a1and Fn1. Although there currently remains no approved pharmacological intervention for NAFLD, a series agents are studied to target associated comorbidities with varying degrees of success. Among them, Orlistat that prevents enteric lipid absorption is targeting obesity, and acts as a reversible lipase inhibitor [37]; Thiazolidinediones, the PPARγ agonists, are proved to be effective in enhancing insulin sensitivity [38]; The lipid-lowering agent statin is mostly used in treating dyslipidemia and mainly regulating cholesterol synthesis [39]; Obeticholic acid, a synthetic variant of chenodeoxycholic acid, is a potent activator of the farnesoid X nuclear receptor, and has been confirmed to improve NASH pathology [40]. As a formula that composed of natural products, it is reasonable that Lingguizhugan decoction was associated with insulin resistance and lipid metabolism. In summary, Lingguizhugan decoction attenuated HFD induced NAFLD possibly by altering insulin resistance and lipid metabolism related pathways (PI3K-Akt, AMPK, etc). Differentially expressed genes involved in these pathways such as Pik3r1, Foxo1, Foxo3, Scd1, Col3a1 and Fn1 might be candidate targets for NAFLD therapy. It is a study of bioinformatics in exploring unknown mechanisms of natural compounds, and the results could infer valuable information for further studies, which might develop new patterns for new drug discovery. Although most of our data were consistent with other studies, several limitations of the present study should be noted. Firstly, the progress of NAFLD may be associated with age and gender. In the present study, the differentially expressed genes were mined from five-weeks-old male rats. Further investigations are needed to validate the candidate targets in groups with different ages and genders. Secondly, we do not know what extent of the altered genes expression acts on protein functions due to posttranslational modifications of proteins such as phosphorylation, ubiquitination, acetylation, lipidation, and glycosylation [41]. Further great efforts should be taken to evaluate protein functions encoding by these identified genes, which may shed new lights on novel treatments for NAFLD.

MATERIALS AND METHODS

Preparation of Lingguizhugan decoction

Lingguizhugan decoction comprises: Poria (main chemicals containing polysaccharides, triterpenes, etc), Ramulus Cinnamomi (main chemicals containing cinnamaldehyde, cinnamic acid, etc), Rhizoma Atractylodis Macrocephalae (main chemicals containing atractylone, polysaccharides, etc), and Radix Glycyrrhizae (main chemicals containing glycyrrhizinic acid, licoflavone, etc). The ratio of the four herbs was 2:1.5:1:1. All herbs were provided by Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine. Herbal decoction was prepared as previously described [42].

Animals and diets

Five- week- old male Wistar rats (130 g ± 10 g) were obtained from Shanghai SLAC Laboratory Animal CO. LTD, China, and maintained in temperature and humidity-controlled room. Twenty one rats were randomly divided into three groups: normal group, fed with chow diet; NAFLD group, fed with HFD (88% chow diet, 10% lard and 2% cholesterol); LGZG group, fed with HFD and administered with Lingguizhugan decoction at a dose of 10 mL/kg/d Animals were weighed and sacrificed after 4-week intervention. Blood samples were harvested from the abdominal aorta, centrifuged at 3000 × g for 10 min at 4 °C and serum was collected. Liver tissue was quickly removed, rinsed with 0.9 % sodium chloride solution and weighed. Two pieces of liver tissue (1.0 cm×1.0 cm×0.2 cm) from the identical lobe and position were obtained and then fixed in 10% neutral-buffered formalin. The other liver tissue was stored at−80°C after snap frozen in liquid nitrogen. All animal procedures were approved by the Animal Experiment Ethics Committee of Shanghai University of Traditional Chinese Medicine

Biochemical analysis

Serum almandine aminotransferase (ALT), AST, TG, TC and liver TG were assayed using commercial kits (obtained from Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturers' instructions.

Histopathological examination

Liver samples were fixed in 10% formalin for 48 hours, embedded in paraffin, sectioned to 4 μm thickness, stained with H&E, and frozen samples were cut into 8 μm sections and stained with Oil Red O, all the samples were examined under a light microscope at 200×magnification.

RNA-Seq detection

Total RNA were isolated from liver tissues (7samples per group) using TRIzol reagent (Invitrogen, USA). RNA quality was verified using Agilent 2100 Bio-analyzer (Agilent Technologies, Santa Clara, CA). cDNA libraries preparation were subsequently performed with reagents supplied in Illumina’s TruSeq RNA sample preparation kit v2 according to the manufacturer’s instructions. The final purified libraries were evaluated using BioAnalyzer 2100 automated electrophoresis system, quantified and sequenced on the HiSeq 2000 according to Illumina’s standard sequencing protocol.

RNA-Seq data analysis

To obtain high-quality clean data for downstream analysis, the low quality reads and reads containing adapters or ploy-N in raw data were removed. Clean reads were aligned with the rat genome (Ensembl RGSC3.4) using TopHat v2.1.1. The reads number mapped to each gene were counted by HTSeq 0.7.2. Fragments Per Kilobase of transcript sequence per millions base pairs sequenced (FPKM) was used to determine the transcription abundance of each gene. Differential expression of three groups (seven biological replicates per group) was analyzed using DESeq 2. False discovery rate<0.05 and fold change >1.2 or <0.83 were used as criteria for significantly differentially expressed genes. Hierarchical cluster analysis was performed using Cluster 3.0 to define differential gene expression patterns. GO and KEGG functional pathways were analyzed by DAVID 6.8 (https://david.ncifcrf.gov/) for differentially expressed genes. Furthermore, PPI network was screened based on BioGRID database using Cytoscape software (http://cytoscape.org/). In the network, nodes represent proteins and edges represent interactions between two proteins.

Statistical analysis

Data were expressed as mean ±SD and were analyzed by one-way analysis of variance (ANOVA) by SPSS v18.0 software. P value less than 0.05 was considered statistically different.
  41 in total

Review 1.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

2.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.

Authors:  Stephen A Harrison; Will Fecht; Elizabeth M Brunt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

Review 3.  Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism.

Authors:  Matthew T Flowers; James M Ntambi
Journal:  Curr Opin Lipidol       Date:  2008-06       Impact factor: 4.776

Review 4.  Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.

Authors:  Yoshikazu Uto
Journal:  Chem Phys Lipids       Date:  2015-09-03       Impact factor: 3.329

Review 5.  Nonalcoholic fatty liver disease - A multisystem disease?

Authors:  Ivana Mikolasevic; Sandra Milic; Tamara Turk Wensveen; Ivana Grgic; Ivan Jakopcic; Davor Stimac; Felix Wensveen; Lidija Orlic
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

Review 6.  Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.

Authors:  Hironori Kitade; Guanliang Chen; Yinhua Ni; Tsuguhito Ota
Journal:  Nutrients       Date:  2017-04-14       Impact factor: 5.717

7.  FOXO transcription factors protect against the diet-induced fatty liver disease.

Authors:  Xiaoyan Pan; Yang Zhang; Hyeong-Geug Kim; Suthat Liangpunsakul; X Charlie Dong
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

Review 8.  Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.

Authors:  Timothy Hardy; Fiona Oakley; Quentin M Anstee; Christopher P Day
Journal:  Annu Rev Pathol       Date:  2016-03-03       Impact factor: 23.472

9.  Traditional Chinese medicine and new concepts of predictive, preventive and personalized medicine in diagnosis and treatment of suboptimal health.

Authors:  Wei Wang; Alyce Russell; Yuxiang Yan
Journal:  EPMA J       Date:  2014-02-13       Impact factor: 6.543

Review 10.  AMP-activated protein kinase: An emerging target for ginseng.

Authors:  Kyong Ju Jeong; Go Woon Kim; Sung Hyun Chung
Journal:  J Ginseng Res       Date:  2013-12-18       Impact factor: 6.060

View more
  11 in total

1.  Modified Linggui Zhugan Decoction () Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1 α Signaling Pathways in Obese Type 2 Diabetic Rats.

Authors:  Jia-Pan Sun; Lin Shi; Fang Wang; Jian Qin; Bin Ke
Journal:  Chin J Integr Med       Date:  2020-11-19       Impact factor: 1.978

2.  Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach.

Authors:  Liang Dai; Jingjuan Xu; Baocheng Liu; Yanqi Dang; Ruirui Wang; Lijie Zhuang; Dong Li; Lulu Jiao; Jianying Wang; Lei Zhang; Linda L D Zhong; Wenjun Zhou; Guang Ji
Journal:  Front Med       Date:  2022-04-26       Impact factor: 4.592

Review 3.  Research progress of signaling pathways of the natural substances intervene dyslipidemia (Review).

Authors:  Ningning Cao; Xiaoxuan Li; Wanjing Zhang; Qingguo Wang; Yujuan Liang; Fujun Zhou; Xuefeng Xiao
Journal:  Exp Ther Med       Date:  2022-06-07       Impact factor: 2.751

4.  Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages.

Authors:  Lin Cao; Erjin Xu; Rendong Zheng; Zhili Zhangchen; Rongling Zhong; Fei Huang; Juan Ye; Hongping Sun; Yaofu Fan; Shaofeng Xie; Yu Chen; Yijiao Xu; Jing Cao; Wen Cao; Chao Liu
Journal:  Chin Med       Date:  2022-01-05       Impact factor: 5.455

Review 5.  Clinical Evidence and Potential Mechanisms of Complementary Treatment of Ling Gui Zhu Gan Formula for the Management of Serum Lipids and Obesity.

Authors:  Jiashuai Huang; Linjing Zhao; Jijia Sun; Lixin Wang; Jianrong Gu; Xijian Liu; Mengwen Yang; Yuting Wang; Ning Zhang; Jiamin Zhu; Shanshan Xu; Xinfeng Ren; Ying Su
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-09       Impact factor: 2.650

Review 6.  Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus.

Authors:  Lung-Wen Tsai; Yi-Hsiang Lu; Rajni Dubey; Jeng-Fong Chiou
Journal:  J Diabetes Res       Date:  2021-11-11       Impact factor: 4.011

7.  MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3.

Authors:  Yiyi Hu; Xuetao Peng; Guoping Du; Zhiqiao Zhang; Yingji Zhai; Xingbo Xiong; Xiaoliang Luo
Journal:  Front Physiol       Date:  2022-02-11       Impact factor: 4.566

8.  Exploration of hub genes involved in PCOS using biological informatics methods.

Authors:  Fei Zhou; Yuling Xing; Tiantian Cheng; Linlin Yang; Huijuan Ma
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

Review 9.  The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism.

Authors:  Sha Li; Yu Xu; Wei Guo; Feiyu Chen; Cheng Zhang; Hor Yue Tan; Ning Wang; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

10.  Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Fuyuan Yang; Jianxiang Zhou; Bo Su; Qiong Zhang; Xuezhi Luo; Fei Wang; Jiangrong Huang; Wei Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-25       Impact factor: 2.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.